Omeros is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing small-molecule and protein therapeutics targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The primary drug candidate in its pipeline of complement-targeted therapeutics is narsoplimab, a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. The OMER stock yearly return is shown above.
The yearly return on the OMER stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OMER annual return calculation with any dividends reinvested as applicable (on ex-dates).
|